The Asia Pacific Glycated Albumin Assay Market should witness market growth of 9.2% CAGR during the forecast period (2023-2030).
Diabetic people have higher levels of protein glycation than non-diabetic patients, glycated proteins can be utilized as a measure of glycemic management. Short-term and postprandial plasma glucose variations are reliably reflected by glycated albumin (GA). Since the glycated albumin assay technique is used to diagnose diabetes, the rising prevalence of the disease is anticipated to fuel market expansion over the coming years. For example, a study by the National Center for Biotechnology Information (NCBI) in October 2021 said that the prevalence of diabetes in India increased from 7.1% in 2009 to 8.9% in 2019.
The market will also profit from the aging populations in developed and developing nations. As the senior population is predicted to increase significantly, it is anticipated that age-related ailments, including diabetes and pancreatic problems, will become significantly more common. Diagnosing and managing such conditions result in many test prescriptions to measure levels of creatinine, albumin, glucose, ketones, and bilirubin, which drives the market's growth.
The prevalence of obesity & overweight, both of which are risk factors for Type 2 diabetes, is increasing in China as a result of bad diets and a lack of exercise. In China, 7% of adults are obese and more than a third are overweight. Children in China are also at risk for developing diabetes as a result of their unhealthy lifestyles, as more than 4 in 5 teenagers between the ages of 11 and 17 do not engage in enough physical exercise, and the prevalence of childhood obesity and overweight is rising quickly. China has the greatest prevalence of Diabetes, as reported by the seventh edition of the International Diabetes Federation (IDF) Diabetes Atlas (11.43 cr.). China has the largest incidence of Diabetes, predominantly type 2, among all nations (114 million), with type 2 being the majority. The high rate of Diabetes will create enormous growth opportunities for market.
The China market dominated the Asia Pacific Glycated Albumin Assay Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $27,799.2 Thousands by 2030. The Japan market is registering a CAGR of 8.5% during (2023-2030). Additionally, The India market would showcase a CAGR of 9.9% during (2023-2030).
Based on Application, the market is segmented into Type 2 Diabetes, Type 1 Diabetes, and Prediabetes. Based on End-user, the market is segmented into Hospitals & Diabetic Care Center, Diagnostic Laboratory, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Asahi Kasei Pharma Corporation(Asahi Kasei Corporation), EKF Diagnostics Holdings plc, Weldon Biotech India Private Limited, Hzymes Biotechnology Co., Ltd., Beijing Strong Biotechnologies, Inc., Diazyme Laboratories, Inc. (General Atomics), Abbexa Limited, Biomatik Corporation, Abnova Corporation and Geno Technology, Inc.
Diabetic people have higher levels of protein glycation than non-diabetic patients, glycated proteins can be utilized as a measure of glycemic management. Short-term and postprandial plasma glucose variations are reliably reflected by glycated albumin (GA). Since the glycated albumin assay technique is used to diagnose diabetes, the rising prevalence of the disease is anticipated to fuel market expansion over the coming years. For example, a study by the National Center for Biotechnology Information (NCBI) in October 2021 said that the prevalence of diabetes in India increased from 7.1% in 2009 to 8.9% in 2019.
The market will also profit from the aging populations in developed and developing nations. As the senior population is predicted to increase significantly, it is anticipated that age-related ailments, including diabetes and pancreatic problems, will become significantly more common. Diagnosing and managing such conditions result in many test prescriptions to measure levels of creatinine, albumin, glucose, ketones, and bilirubin, which drives the market's growth.
The prevalence of obesity & overweight, both of which are risk factors for Type 2 diabetes, is increasing in China as a result of bad diets and a lack of exercise. In China, 7% of adults are obese and more than a third are overweight. Children in China are also at risk for developing diabetes as a result of their unhealthy lifestyles, as more than 4 in 5 teenagers between the ages of 11 and 17 do not engage in enough physical exercise, and the prevalence of childhood obesity and overweight is rising quickly. China has the greatest prevalence of Diabetes, as reported by the seventh edition of the International Diabetes Federation (IDF) Diabetes Atlas (11.43 cr.). China has the largest incidence of Diabetes, predominantly type 2, among all nations (114 million), with type 2 being the majority. The high rate of Diabetes will create enormous growth opportunities for market.
The China market dominated the Asia Pacific Glycated Albumin Assay Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $27,799.2 Thousands by 2030. The Japan market is registering a CAGR of 8.5% during (2023-2030). Additionally, The India market would showcase a CAGR of 9.9% during (2023-2030).
Based on Application, the market is segmented into Type 2 Diabetes, Type 1 Diabetes, and Prediabetes. Based on End-user, the market is segmented into Hospitals & Diabetic Care Center, Diagnostic Laboratory, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Asahi Kasei Pharma Corporation(Asahi Kasei Corporation), EKF Diagnostics Holdings plc, Weldon Biotech India Private Limited, Hzymes Biotechnology Co., Ltd., Beijing Strong Biotechnologies, Inc., Diazyme Laboratories, Inc. (General Atomics), Abbexa Limited, Biomatik Corporation, Abnova Corporation and Geno Technology, Inc.
Scope of the Study
By Application
- Type 2 Diabetes
- Type 1 Diabetes
- Prediabetes
By End-user
- Hospitals & Diabetic Care Center
- Diagnostic Laboratory
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Asahi Kasei Pharma Corporation(Asahi Kasei Corporation)
- EKF Diagnostics Holdings plc
- Weldon Biotech India Private Limited
- Hzymes Biotechnology Co., Ltd.
- Beijing Strong Biotechnologies, Inc.
- Diazyme Laboratories, Inc. (General Atomics)
- Abbexa Limited
- Biomatik Corporation
- Abnova Corporation
- Geno Technology, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Glycated Albumin Assay Market by Application
Chapter 5. Asia Pacific Glycated Albumin Assay Market by End User
Chapter 6. Asia Pacific Glycated Albumin Assay Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Asahi Kasei Pharma Corporation (Asahi Kasei Corporation)
- EKF Diagnostics Holdings plc
- Weldon Biotech India Private Limited
- Hzymes Biotechnology Co., Ltd.
- Beijing Strong Biotechnologies, Inc.
- Diazyme Laboratories, Inc. (General Atomics)
- Abbexa Limited
- Biomatik Corporation
- Abnova Corporation
- Geno Technology, Inc.
Methodology
LOADING...
